TIL News and Press, Instil Bio Inc. From 12/08/22

Discontinuing unmodified TIL programs, including DELTA-1 and DELTA-2 trials of ITIL-168 Prioritizing CoStAR-TIL programs for clinical development, including ITIL-306 in Phase 1 trial for NSCLC, ovarian, and renal cell carcinoma Reducing U.S. headcount by approximately 60% ...

Instil Bio press release ( NASDAQ: TIL ): Q3 GAAP EPS of -$0.43. As of Sept.30, 2022, the company had $303.3M in total cash and cash equivalents and marketable securities. The company expects that its cash, cash equivalents and marketable securities as of September ...

Manufacturing update on voluntary pause of DELTA-1 trial of ITIL-168 in advanced melanoma expected in Q1’23 Reprioritization of resources with enrollment deferred in DELTA-2 trial of ITIL-168 First patient with non-small cell lung cancer dosed with ITIL-306, the f...

DALLAS, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced poster presentation...

Boston, Massachusetts--(Newsfile Corp. - November 3, 2022) - Block & Leviton is investigating Instil Bio, Inc. (NASDAQ: TIL) for potential securities law violations. Investors who have lost money in their Instil Bio, Inc. investment should contact the firm to learn more about how they mi...

BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Instil Bio, Inc. (NASDAQ: TIL) for potential securities law violations. Investors who have lost money in their Instil Bio, Inc. investment should contact the firm to learn more about how they might recover th...

Instil Bio, Inc. ( NASDAQ: TIL ), a cancer-focused biotech, dropped 35% pre-market Monday after announcing that the company voluntarily paused enrollment in its ongoing clinical trials of the lead TIL product candidates ITIL-168 and ITIL-306 after a production issue. T...

Voluntarily paused enrollment in ITIL-168 and ITIL-306 trials pending outcome of manufacturing analysis and implementation of corrective actions No regulatory agency, including the FDA, has notified the Company of a clinical hold in any of its clinical trials Obs...

• ITIL-306 is a novel TIL therapy engineered with our CoStAR platform (CoStAR-TIL) targeting folate receptor alpha which is designed to boost TIL activity in the tumor microenvironment •  CoStAR-T cells demonstrate enhanced proliferation and other effector funct...

DALLAS, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that company manag...